文化适配在线地中海饮食干预用于代谢功能障碍相关脂肪性肝病(TIMA):随机对照试验研究方案
本研究为12周单中心双臂平行随机对照试验,纳入符合MASLD临床诊断且MRI-PDFF肝脂肪含量≥5%的成人,随机接受等热量文化适配地中海饮食干预或标准护理。干预组接受4次实时视频咨询及每周基于行为改变技术的短信支持,主要结局为第12周MRI-PDFF肝内脂肪相对变化。
要点
- 纳入标准为MASLD临床诊断且MRI-PDFF肝脂肪含量≥5%的成人。
- 干预组接受4次实时视频饮食咨询(第0、3、6、9周)及每周BCT短信。
- 主要结局为第12周MRI-PDFF肝内脂肪含量相对变化。
核心结论
- 该试验旨在评估文化适配地中海饮食干预对MASLD患者肝脏脂肪的影响,结果尚未报告。
研究设计与样本
- 12周单中心双臂平行随机对照试验,注册号NCT06503120,2024年7月9日注册。
- 纳入符合MASLD临床诊断且MRI-PDFF肝脂肪含量≥5%的成人。
- 随机分配至等热量文化适配地中海饮食干预组或标准护理组。
关键数值与推荐
- 干预组接受4次结构化实时视频咨询,每次15-20分钟,分别在第0、3、6、9周。
- 咨询由注册营养师通过在线平台提供,依据3天拍照饮食日记和台湾版地中海饮食依从性筛查评分。
- 干预组每周接受基于行为改变技术的短信,针对个体饮食差距并强化依从性。
- 主要结局为第12周MRI-PDFF评估的肝内脂肪含量相对变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Mediterranean diet (MedDiet) is widely recognized for its beneficial effects on hepatic steatosis. However, optimal strategies to support dietary adherence among patients with metabolic dysfunction-associated steatotic liver disease (MASLD), particularly in non-Mediterranean regions where the MedDiet is not habitual, remain underexplored. OBJECTIVE: To evaluate the effectiveness of a culturally adapted MedDiet for MASLD through the implementation of real-time video counseling combined with behavior change techniques (BCTs). METHODS: This is a 12-week, single-center, two-arm, parallel-group randomized controlled trial registered at ClinicalTrials.gov (identifier: NCT06503120). Adults who fulfill the clinical diagnosis of MASLD and have ≥ 5% hepatic fat content on MRI-PDFF will be randomly assigned to receive either an isocaloric culturally adapted MedDiet intervention or standard care. The intervention comprises two components. First, participants will receive four structured real-time video counseling sessions (15-20 min each) at weeks 0, 3, 6, and 9. These sessions will be delivered by a registered dietitian via an online platform, guided by each participant's 3-day photographic food diary and a Taiwanese version Mediterranean Diet Adherence Screener scores to provide personalized dietary advice. Second, participants will receive weekly text messages underpinned by BCTs to address individual dietary gaps and reinforce adherence. The primary outcome is the relative change in intrahepatic fat content, assessed by MRI-PDFF at week 12. Secondary outcomes include the changes in liver enzymes, lipid profile, liver stiffness, serum metabolites, gut microbiota composition, dietary adherence, quality of life, and anthropometric measures. DISCUSSION: This is the first randomized controlled trial to evaluate a fully remote, dietitian-led culturally adapted MedDiet intervention using real-time video counseling and text-based BCTs in patients with MASLD. This approach may support scalable, patient-centered dietary strategies for improving liver and metabolic health in this population. TRIAL REGISTRATION: ClinicalTrials.gov NCT06503120. Registered on July 9, 2024.
引用
- Lin YC, Wang JR, Su TC, et al. A culturally adapted online Mediterranean diet intervention for metabolic dysfunction-associated steatotic liver disease (TIMA): study protocol for a randomized controlled trial. Trials. 2026. PMID: 42216178. doi:10.1186/s13063-026-09819-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。